Papillary thyroid cancer (PTC) generally has a good prognosis, with 5-year relative survival rates of 99% for regional cancer that has spread to the lymph nodes. PTC is the most common type of thyroid ...

The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity ...

Buparlisib plus paclitaxel did not improve overall survival compared to paclitaxel alone in PD-1/PD-L1-pretreated recurrent/metastatic HNSCC patients. The combination showed a higher overall response ...

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and ...

Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.